Skip to content

Landiolol on cerebral autoregulation and neurlogical outcome in patients with sepsis

Landiolol on cerebral autoregulation and neurlogical outcome in patients with sepsis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093445
Enrollment
Unknown
Registered
2024-12-05
Start date
2024-03-22
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

The landiolol group:Besides standard treatment for sepsis, participants randomised to this arm will receive landiolol. The continuous intravenous infusion of landiolol was started at 1.0 µg/kg/min, in
The standard group:Participants randomised to this arm will receive standard care only for sepsis but not receive any beta blockade for the duration of their ICU stay. If the treating clinician deems

Sponsors

The Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Infection was present and SOFA score >=2 points 2.Receiving adequate fluid resuscitation to reach central venous pressure of 8-12 mmHg,and to maintain a target blood pressure at 65 mmHg or higher ,and heart rate >=100 bpm ( at the time of randomisation); 3.Performing invasive hemodynamic monitoring; 4.Expecting the length of ICU stay is greater than 48 hours; 5.Aged 18 years or above .

Exclusion criteria

Exclusion criteria: 1.Having been treated with ß blockers within one month prior to admission; 2.Having pre-existing severe cardiac dysfunction (NYHA grade 3 or more) ,heart block and tachyarrhythmia; 3.Factors affecting the results of NIRS monitoring include surgery involving frontal lobe lesions, frontal contusion and laceration, bilateral frontal scalp hematoma, decompressive craniotomy, subdural or epidural hematoma, effusion, gas, cerebral hemorrhage, tumor, intracranial infection, and cerebral ischemia; 4.Pregnant woman.

Design outcomes

Primary

MeasureTime frame
Cerebral oxygenation index,COX;

Secondary

MeasureTime frame
Regional cerebral oxygen saturation, rSO2;Peak systolic velocity of the middle cerebral artery;End diastolic velocity of the middle cerebral artery;Mean velocity of the middle cerebral artery;Resistance index of the middle cerebral artery;Pulsatility index of the middle cerebral artery;Picco/Vigileo hemodynamic parameter;Inflammatory mediator indicators;Inflammatory response indicators;The Confusion Assessment Method-Intensive Care Unit,CAM-ICU;The Glasgow Coma Scale,GCS;28-Day Mortality;

Countries

China

Contacts

Public ContactBaochun Zhou

The Second Affiliated Hospital of Soochow University

zbc76@139.com+86 136 0613 6868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026